Innatal noninvasive prenatal screening is backed by a peer-reviewed, high powered study.
We upgraded the Innatal® Prenatal screen in October 2018 with the latest sequencing technology and improved chemistry.
Data supporting top performance in this upgraded test was then published in the Journal of Medical Screening.1 Verification and validation of this test were conducted as prescribed by multiple peer-reviewed guidelines.2,3,4 This clinical study was blinded and adjudicated by a third party.
What did we find?
Innatal is a cfDNA prenatal screen you can trust.
Precise – Agreement of >99% for repeatability and reproducibility
Accurate – High concordance with known clinical outcomes
Sensitive – Proven to identify affected fetuses with >99% sensitivity
Specific – Proven to rule-out unaffected fetuses with >99% specificity
Limited failure – Clear answers the first time with a low failure rate (~1%)
Validation data was published in the Journal of Medical Screening (Sep. 2019).Read the manuscript